Robertson NP - Search Results

1

Understanding mechanisms and treatments for neuropathic disease.

Harding K, Robertson NP. Harding K, et al. Among authors: robertson np. J Neurol. 2012 Jul;259(7):1509-11. doi: 10.1007/s00415-012-6587-2. J Neurol. 2012. PMID: 22743793 No abstract available.

2

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Hirst CL, Pace A, Pickersgill TP, Jones R, McLean BN, Zajicek JP, Scolding NJ, Robertson NP. Hirst CL, et al. Among authors: robertson np. J Neurol. 2008 Feb;255(2):231-8. doi: 10.1007/s00415-008-0696-y. Epub 2008 Feb 20. J Neurol. 2008. PMID: 18283404

3

The genetic aetiology of late-onset chronic progressive cerebellar ataxia. A population-based study.

Wardle M, Majounie E, Muzaimi MB, Williams NM, Morris HR, Robertson NP. Wardle M, et al. Among authors: robertson np. J Neurol. 2009 Mar;256(3):343-8. doi: 10.1007/s00415-009-0015-2. Epub 2009 Mar 6. J Neurol. 2009. PMID: 19259763

4

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP. Marsh EA, et al. Among authors: robertson np. J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6. J Neurol. 2010. PMID: 20049473 Clinical Trial.

5

Complement regulator factor H as a serum biomarker of multiple sclerosis disease state.

Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP. Ingram G, et al. Among authors: robertson np. Brain. 2010 Jun;133(Pt 6):1602-11. doi: 10.1093/brain/awq085. Epub 2010 Apr 25. Brain. 2010. PMID: 20421219

6

Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity.

Ingram G, Bugert JJ, Loveless S, Robertson NP. Ingram G, et al. Among authors: robertson np. Eur J Neurol. 2010 Nov;17(11):1386-9. doi: 10.1111/j.1468-1331.2010.03083.x. Eur J Neurol. 2010. PMID: 20482607

7

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.

Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Cossburn M, et al. Among authors: robertson np. Neurology. 2011 Aug 9;77(6):573-9. doi: 10.1212/WNL.0b013e318228bec5. Epub 2011 Jul 27. Neurology. 2011. PMID: 21795656 Clinical Trial.

8

The C9ORF72 syndrome: implications for clinical practice.

Robertson NP. Robertson NP. J Neurol. 2012 Apr;259(4):794-6. doi: 10.1007/s00415-012-6479-5. J Neurol. 2012. PMID: 22430253 No abstract available.

9

New and old: notable drug developments for clinical practice.

Robertson NP. Robertson NP. J Neurol. 2012 May;259(5):1003-5. doi: 10.1007/s00415-012-6518-2. J Neurol. 2012. PMID: 22527241 No abstract available.

10

The interaction between acquired mitochondrial disease and neurodegeneration.

Harding K, Robertson NP. Harding K, et al. Among authors: robertson np. J Neurol. 2012 Aug;259(8):1761-3. doi: 10.1007/s00415-012-6614-3. J Neurol. 2012. PMID: 22825794 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters